CO5150210A1 - Tratamiento de bph con agentes elevadores del cgmp - Google Patents

Tratamiento de bph con agentes elevadores del cgmp

Info

Publication number
CO5150210A1
CO5150210A1 CO99066723A CO99066723A CO5150210A1 CO 5150210 A1 CO5150210 A1 CO 5150210A1 CO 99066723 A CO99066723 A CO 99066723A CO 99066723 A CO99066723 A CO 99066723A CO 5150210 A1 CO5150210 A1 CO 5150210A1
Authority
CO
Colombia
Prior art keywords
administered
cgmp
pde inhibitor
cgmp pde
bph treatment
Prior art date
Application number
CO99066723A
Other languages
English (en)
Inventor
Michael Gran Wyllie
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of CO5150210A1 publication Critical patent/CO5150210A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La BPH en seres humanos masculinos, las contracciones de vejigas inestables en seres humanos femeninos y los LUTS tanto en varones como en mujeres se pueden tratar administrando por vía oral una cantidad eficaz de un inhibidor de las PDE del CGMP a un paciente que necesite de dicho tratamiento. El inhibidor de la PDE del CGMP puede ser coadministrado junto con un agente antagonista adrenérgico de a. Cuando se administra una combinación de un inhibidor de las PDE del CGMP y un antagonista adrenérgico de a, estos componentes se pueden administrar conjuntamente en una composición o pueden administrar por separado. Si se administran por separado, pueden estar materializados en forma de un estuche.<EMI FILE="99066723_1" ID="1" IMF=JPEG >
CO99066723A 1998-10-21 1999-10-21 Tratamiento de bph con agentes elevadores del cgmp CO5150210A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10509798P 1998-10-21 1998-10-21

Publications (1)

Publication Number Publication Date
CO5150210A1 true CO5150210A1 (es) 2002-04-29

Family

ID=22304008

Family Applications (1)

Application Number Title Priority Date Filing Date
CO99066723A CO5150210A1 (es) 1998-10-21 1999-10-21 Tratamiento de bph con agentes elevadores del cgmp

Country Status (11)

Country Link
EP (1) EP1020190A3 (es)
JP (1) JP2000128804A (es)
KR (1) KR20000029222A (es)
AR (1) AR020850A1 (es)
AU (1) AU5597799A (es)
CA (1) CA2287122A1 (es)
CO (1) CO5150210A1 (es)
HU (1) HUP9903732A3 (es)
IL (1) IL132406A0 (es)
PE (1) PE20001282A1 (es)
ZA (1) ZA996622B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW536402B (en) 1998-06-26 2003-06-11 Yamanouchi Pharma Co Ltd Pharmaceutical composition for the therapy of voiding dysfunction
PT1219609E (pt) 1999-09-16 2007-06-19 Tanabe Seiyaku Co ''compostos cíclicos aromático azotados de seis membros''
TWI265925B (en) 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
US7273868B2 (en) 2000-04-28 2007-09-25 Tanabe Seiyaku Co., Ltd. Pyrazine derivatives
AU4114201A (en) 2000-04-28 2001-11-12 Tanabe Seiyaku Co Cyclic compounds
IT1318674B1 (it) * 2000-08-08 2003-08-27 Nicox Sa Faramaci per l'incontinenza.
JP2001288115A (ja) * 2001-02-07 2001-10-16 Yamanouchi Pharmaceut Co Ltd 下部尿路症治療剤
EP1364659B1 (en) 2001-02-08 2009-11-11 Ono Pharmaceutical Co., Ltd. Remedies for urinary diseases comprising lpa receptor controlling agents
EP1364950A4 (en) 2001-02-26 2005-03-09 Tanabe Seiyaku Co PYRIDOPYRIMIDINE OR NAPHTHYRIDINE DERIVATIVE
DE10135815A1 (de) * 2001-07-23 2003-02-06 Bayer Ag Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen
KR20080056250A (ko) * 2005-09-29 2008-06-20 바이엘 헬스케어 아게 비뇨기 장애의 치료를 위한 ｐｄｅ 억제제 및 이들의 조합
US20070093493A1 (en) * 2005-10-12 2007-04-26 Lilly Icos Llc Treatment of benign prostatic hypertrophy and lower urinary tract symptoms
TW200733975A (en) * 2005-12-20 2007-09-16 Pfizer Prod Inc Pharmaceutical combination for the treatment of luts
JP2010540621A (ja) * 2007-10-02 2010-12-24 ドン ア ファーマシューティカル カンパニー リミテッド 良性前立腺肥大症および下部尿路症状の治療または予防用組成物、およびその治療または予防方法
KR20110062943A (ko) * 2009-12-04 2011-06-10 주식회사종근당 퀴나졸린 유도체를 유효성분으로 하는 전립선 비대증 예방 또는 치료제
CN104507489B (zh) 2012-05-11 2016-07-13 杰姆维克斯&凯尔有限公司 用于预防和治疗类风湿性关节炎的组合物
KR20150014483A (ko) 2012-05-11 2015-02-06 주식회사 카엘젬백스 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물
WO2014010971A1 (ko) 2012-07-11 2014-01-16 주식회사 카엘젬백스 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물
ES2716870T3 (es) 2013-04-19 2019-06-17 Gemvax & Kael Co Ltd Composición para el tratamiento y prevención de lesión isquémica
US10383926B2 (en) 2013-06-07 2019-08-20 Gemvax & Kael Co., Ltd. Biological markers useful in cancer immunotherapy
ES2808076T3 (es) 2013-06-21 2021-02-25 Gemvax & Kael Co Ltd Regulador de la secreción hormonal, composición que lo contiene y procedimiento para controlar la secreción hormonal mediante su uso
CN110755599A (zh) 2013-10-23 2020-02-07 珍白斯凯尔有限公司 用于治疗和预防良性前列腺增生的组合物
EP3072519B1 (en) 2013-11-22 2020-08-19 Gemvax & Kael Co., Ltd. Peptide having angiogenesis inhibitory activity and composition containing same
EP3085380B1 (en) 2013-12-17 2020-06-17 Gemvax & Kael Co., Ltd. Composition for treating prostate cancer
US9937240B2 (en) 2014-04-11 2018-04-10 Gemvax & Kael Co., Ltd. Peptide having fibrosis inhibitory activity and composition containing same
JP6466971B2 (ja) 2014-04-30 2019-02-06 ジェムバックス アンド カエル カンパニー，リミティド 臓器、組織又は細胞移植用組成物、キット及び移植方法
KR102413243B1 (ko) 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
KR102636129B1 (ko) 2015-02-27 2024-02-14 주식회사 젬백스앤카엘 청력 손상 방어용 펩타이드 및 이를 포함하는 조성물
KR102638286B1 (ko) 2015-07-02 2024-02-20 주식회사 젬백스앤카엘 항바이러스 활성 효능을 가지는 펩티드 및 이를 포함하는 조성물
KR20180123512A (ko) 2016-04-07 2018-11-16 주식회사 젬백스앤카엘 텔로머라제 활성 증가 및 텔로미어 연장 효능을 가지는 펩티드 및 이를 포함하는 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9114760D0 (en) * 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
GB9401090D0 (en) * 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
DE19540642A1 (de) * 1995-11-01 1997-05-07 Stief Christian Georg Priv Doz Verwendung von Inhibitoren der Phosphodiesterase bei der Behandlung von Prostataerkrankungen
DE19642322A1 (de) * 1996-10-14 1998-04-16 Bayer Ag Neue 3-Heterocyclyl-substituierte Pyrazolderivate
DE19709126A1 (de) * 1997-03-06 1998-09-10 Bayer Ag Arylamin-, -oxy-, -thio-substituierte Dihydropurinone und Pyrazolopyrimidine
WO1999002161A1 (en) * 1997-07-09 1999-01-21 Forssmann Wolf Georg Use of phosphordiesterase inhibitors in the treatment of prostatic diseases

Also Published As

Publication number Publication date
KR20000029222A (ko) 2000-05-25
ZA996622B (en) 2001-04-20
JP2000128804A (ja) 2000-05-09
AR020850A1 (es) 2002-05-29
AU5597799A (en) 2000-05-04
IL132406A0 (en) 2001-03-19
EP1020190A3 (en) 2000-10-25
CA2287122A1 (en) 2000-04-21
HUP9903732A3 (en) 2002-01-28
PE20001282A1 (es) 2000-11-18
HU9903732D0 (en) 1999-12-28
EP1020190A2 (en) 2000-07-19
HUP9903732A2 (hu) 2000-08-28

Similar Documents

Publication Publication Date Title
CO5150210A1 (es) Tratamiento de bph con agentes elevadores del cgmp
DE59709992D1 (de) Ubichinon enthaltendes nicht alkoholisches getränk
UY27465A1 (es) Métodos y composiciones para tratar flavivirus y pestivirus con 4&#39; modificaciones nucleosides
TW200505434A (en) Therapeutic treatment
CO4970819A1 (es) Tratamiento de disfuncion sexual femenina en una hembra humana
CO5570109A1 (es) Compuestos de dihidropirimidina heterociclicos
UY27890A1 (es) Tratamiento terapeutico
PA8502901A1 (es) Tratamiento de combinacion con il-1ra y compuestos que inhiben el procesamiento y la liberacion de il-1
BR0111800A (pt) Combinações de inibidores de depeptidil peptidase iv e outros agentes antidiabéticos para o tratamento de diabete mellitus
AR035642A1 (es) Uso de una composicion de celecoxib para el alivio rapido del dolor
ES2174465T3 (es) Compuestos triazol y su utilizacion como ligandos de dopamina-d.
PE20010924A1 (es) Compuestos inhibidores de fosfodiesterasa utiles para el tratamiento de la disfuncion sexual femenina
GB0025173D0 (en) Therapeutic agents
DK1049378T3 (da) Antimikrobiel sammensætning
NZ509807A (en) Pharmaceutical combinations for treating lower urinary tract symptoms associated with Benign Prostatic Hyperplasia (BHP) comprising alpha-adrenoceptor and muscarinic antagonists
UY27296A1 (es) Composición farmacéutica que contiene mosaprida y pancreatina
CO5241299A1 (es) Aparato y metodo para administrar una pulverizacion medicinal
ITMI922331A1 (it) Uso di paratormone, suoi frammenti biologicamente attivi e peptidi correlati, per la preparazione di composizioni farmaceutiche utili nella prevenzione e terapia dell&#39;aborto e del parto pretermine ed in generale per il trattamento della gestazione
AR037047A1 (es) Baja concentracion de peroxido para el tratamiento o prevencion de enfermedades vaginales
EA199700150A1 (ru) КОМБИНИРОВАННОЕ ЛЕЧЕНИЕ ПО ПОВОДУ ВИЧ ИНФЕКЦИИ С ИСПОЛЬЗОВАНИЕМ ИНГИБИТОРА ПРОТЕАЗЫ ВИЧ ИНДИНАВИРА И ИНГИБИТОРА ОБРАТНОЙ ТРАНСКРИПТАЗЫ 3TC, НЕОБЯЗАТЕЛЬНО СОВМЕСТНО С AZT, ddI ИЛИ ddC
RU2002109259A (ru) Способ лечения доброкачественных заболеваний шейки матки
ES2162433T3 (es) Procedimiento para el tratamiento del clinker de cemento.
AR025308A1 (es) Composiciones y metodos para tratar condiciones alergicas e inflamatorias con tos.
AR024438A1 (es) Antagonista hormonal liberador de gonadotropina
Alcorn Epidemiology and public health